Publications by authors named "Julianne Darling"
Article Synopsis
- Cholangiocarcinoma is a bile duct cancer often diagnosed late, leading to poor prognosis, but selective FGFR inhibitors show promise in treating it, especially in cases with specific genetic alterations.
- These FGFR inhibitors can cause side effects like hyperphosphatemia, fatigue, and other gastrointestinal and dermatological issues, which need to be managed proactively to improve treatment adherence and patient outcomes.
- A multidisciplinary care team including various healthcare professionals is essential, with practical guidance provided on managing side effects, considering interactions with other medications or foods, and offering supportive care recommendations for patients.
Introduction: To date, there is no adherence estimator to identify risk of nonadherence prior to initiating oral oncolytics.
Methods: A workgroup was assembled through the National Community Oncology Dispensing Association and tasked with creating a tool to meet this need. Tool constructs were defined after a review of the literature identifying top barriers to adherence.
Oral Antineoplastics in Acute Myeloid Leukemia: A Comprehensive Review.
Clin Lymphoma Myeloma Leuk
December 2022
Article Synopsis
- AML is a complex disease with a poor long-term survival rate, showing significant biological and clinical variation.
- Recent advancements in genetic research and new drug approvals have revitalized treatment options for AML, especially after decades of limited progress.
- Clinicians need to be well-informed about the specifics of new oral anti-leukemic medications, including their unique administration, side effects, and monitoring requirements, to effectively manage patients with AML.*
Purpose: As the utilization of oral cancer medications rises, it is vital that cancer centers track costs associated with these expensive medications. This research seeks to report the cost interventions associated with medically integrated pharmacies (MIPs) and mail-order pharmacies.
Methods: Data collection occurred from October 2016 through May 2021.
Cabozantinib is an oral multikinase inhibitor whose targets include vascular endothelial growth factor receptors, MET, and the TAM family of kinases (TYRO3, AXL, MER). Cabozantinib is approved for patients with advanced hepatocellular carcinoma who have been previously treated with sorafenib, based on improved overall survival and progression-free survival relative to placebo in the phase III CELESTIAL study. During CELESTIAL, the most common adverse events (AEs) experienced by patients receiving cabozantinib included palmar-plantar erythrodysesthesia, fatigue, gastrointestinal-related events, and hypertension.
View Article and Find Full Text PDFOral chemotherapy represents a major patient-centric advancement in therapy convenience. However, ownership of safe and correct administration of these agents requires significant patient education. To address this challenge, an in-person pharmacist-led oral chemotherapy education clinic in gastrointestinal oncology patients within an academic medical center was created and assessed.
View Article and Find Full Text PDF